课题基金 / 基金详情

CORTIVAZOL--PHASE I TRIAL IN PATIENTS WITH INCURABLE MALIGNANCIES

CORTIVAZOL--PHASE I TRIAL IN PATIENTS WITH INCURABLE MALIGNANCIES
考替伐唑——针对无法治愈的恶性肿瘤患者的 I 期试验
批准号:
6246340
负责人:
E B THOMPSON
金额:
$2.71万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-01-06 至 1997-11-30

项目摘要

项目成果

E B THOMPSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A phase I clinical oncology trial of cortivazol, a potent glucocorticoid, in patients with various malignancies is proposed. The purpose of the study is to determine the toxicity and maximum tolerated dose (MTD) of cortivazol in humans. Cortivazol in DMSO solution will be given to patients intravenously on a schedule of 5 days on/9 days off. The doses will increase until MTD is reached.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multidisciplinary Training in Cancer Research
Multidisciplinary Training in Cancer Research
Multidisciplinary Training in Cancer Research
FASEB Summer Conference on the Dynamic Structure of the Nuclear Hormone Receptors
海外基金